FI106027B - Menetelmä (S)(+)-2-etoksi-4-[N-[1-(2-piperidinofenyyli)-3-metyyli-1-butyyli] aminokarbonyylimetyyli]-betsoehapon tai sen suolan valmistamiseksi sekä (S)-1-(2-piperidinofenyyli)-3-metyyli-1-butyyliamiinin N-asetyyli-L-glutamiinisuola sen valmistus - Google Patents

Menetelmä (S)(+)-2-etoksi-4-[N-[1-(2-piperidinofenyyli)-3-metyyli-1-butyyli] aminokarbonyylimetyyli]-betsoehapon tai sen suolan valmistamiseksi sekä (S)-1-(2-piperidinofenyyli)-3-metyyli-1-butyyliamiinin N-asetyyli-L-glutamiinisuola sen valmistus Download PDF

Info

Publication number
FI106027B
FI106027B FI935724A FI935724A FI106027B FI 106027 B FI106027 B FI 106027B FI 935724 A FI935724 A FI 935724A FI 935724 A FI935724 A FI 935724A FI 106027 B FI106027 B FI 106027B
Authority
FI
Finland
Prior art keywords
group
methyl
compound
phenyl
general formula
Prior art date
Application number
FI935724A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI935724A0 (fi
FI935724A (fi
Inventor
Michael Mark
Eckhard Rupprecht
Andreas Greischel
Wolfgang Grell
Ulrich Mueller
Gabriele Zahn
Hansjoerg Knorr
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36781542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI106027(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA002111851A external-priority patent/CA2111851C/fr
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of FI935724A0 publication Critical patent/FI935724A0/fi
Publication of FI935724A publication Critical patent/FI935724A/fi
Application granted granted Critical
Publication of FI106027B publication Critical patent/FI106027B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
FI935724A 1991-06-21 1993-12-20 Menetelmä (S)(+)-2-etoksi-4-[N-[1-(2-piperidinofenyyli)-3-metyyli-1-butyyli] aminokarbonyylimetyyli]-betsoehapon tai sen suolan valmistamiseksi sekä (S)-1-(2-piperidinofenyyli)-3-metyyli-1-butyyliamiinin N-asetyyli-L-glutamiinisuola sen valmistus FI106027B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP9101147 1991-06-21
CA2111851 1991-06-21
CA002111851A CA2111851C (fr) 1991-06-21 1991-06-21 Acide (s)(+)-2-ethoxy-4-{n-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl}benzoique
PCT/EP1991/001147 WO1993000337A1 (fr) 1991-06-21 1991-06-21 Acides (s)(+)-2-ethoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoique
SG9602715 1991-06-21
SG1996002715A SG43036A1 (en) 1991-06-21 1991-06-21 (S) (+) -2-ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl- 1-buthyl]aminocarbony methyl] - benzoic a cid
CN91104984A CN1048722C (zh) 1991-06-21 1991-07-22 (s)(+)-2-乙氧基-4-[n-[1-(2-哌啶子基-苯基)-3-甲基-1-丁基]氨基羰基甲基]苯甲酸,含该化合物的药物组合物及其制备方法
CN91104984 1991-07-22

Publications (3)

Publication Number Publication Date
FI935724A0 FI935724A0 (fi) 1993-12-20
FI935724A FI935724A (fi) 1993-12-20
FI106027B true FI106027B (fi) 2000-11-15

Family

ID=36781542

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935724A FI106027B (fi) 1991-06-21 1993-12-20 Menetelmä (S)(+)-2-etoksi-4-[N-[1-(2-piperidinofenyyli)-3-metyyli-1-butyyli] aminokarbonyylimetyyli]-betsoehapon tai sen suolan valmistamiseksi sekä (S)-1-(2-piperidinofenyyli)-3-metyyli-1-butyyliamiinin N-asetyyli-L-glutamiinisuola sen valmistus

Country Status (8)

Country Link
EP (1) EP0589874B1 (fr)
JP (1) JP2921982B2 (fr)
CN (1) CN1048722C (fr)
AU (1) AU660930B2 (fr)
FI (1) FI106027B (fr)
NO (2) NO303687B1 (fr)
SG (1) SG43036A1 (fr)
WO (1) WO1993000337A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159184T3 (es) * 1997-06-13 2001-09-16 Novo Nordisk As Nueva posologia para la dmni.
IN192862B (fr) 1999-11-16 2004-05-22 Ranbaxy Lab Ltd
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
EP2266590A3 (fr) 2002-02-22 2011-04-20 Shire LLC Système d'administration de substances actives et méthodes de protection et d'administration de substances actives
AU2003260078A1 (en) * 2002-08-23 2004-03-11 Dr. Reddy's Laboratories Limited Crystalline and amorphous forms of (s) -repaglinide and the processes for preparation thereof
US7915421B2 (en) 2003-05-14 2011-03-29 Cilag Ltd. Method for preparing phenyl acetic acid derivatives
AU2003237595A1 (en) * 2003-05-26 2004-12-13 Biocon Limited Process for the preparation of s(+)-2-ethoxy-4-(n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl)benzoic acid derivatives
WO2005021524A1 (fr) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Procede pour la preparation d'une forme amorphe de repaglinide
CN1305863C (zh) * 2004-12-27 2007-03-21 浙江大学 (s)－异丙基－(2－哌啶)苯基－甲基胺的合成方法
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
FR2898894B1 (fr) * 2006-03-24 2008-06-06 Genfit Sa Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
CA2666846C (fr) 2006-10-20 2018-04-10 Cpd, Llc Procede pour retablir l'effet de l'incretine
US8101769B2 (en) * 2007-02-15 2012-01-24 Actavis Group Ptc Ehf Process for preparing ethyl (S)-2-ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonyl methyl]benzoate and use thereof for the preparation of Repaglinide
US20100197732A1 (en) * 2007-06-06 2010-08-05 Actavis Group Ptc Ehf Repaglinide Substantially Free of Dimer Impurity
EP2019097A1 (fr) * 2007-07-25 2009-01-28 Aurobindo Pharma Limited Procédé de préparation de (alphaS)-alpha-(2-méthylpropyl)-2-(1-piperidinyl)benzèneméthanamine
DE102008046995B4 (de) * 2008-09-12 2010-08-26 Stada Arzneimittel Ag 2-Ethoxy-benzoesäurederivat
EP2177221A1 (fr) 2008-10-20 2010-04-21 Krka Tovarna Zdravil, D.D., Novo Mesto Procedure de préparation de répaglinide essentielment optiquement pur et ses précurseurs
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
EP2430018B1 (fr) 2009-05-15 2013-07-03 Novartis AG Dérivés de benzoxazolone en tant qu'inhibiteurs d'aldostérone synthase
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
EP2501678B1 (fr) 2009-11-17 2015-09-23 Novartis AG Dérivés de l'arylpyridine comme inhibiteurs de l'aldosterone synthase.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011064376A1 (fr) 2009-11-30 2011-06-03 Novartis Ag Dérivés d'imidazole en tant qu'inhibiteurs de l'aldostérone synthase
EP2364977A1 (fr) 2010-01-26 2011-09-14 Reuter Chemische Apparatebau KG Procédé d'enrichissement énantiomérique de 3-methyl-1-(2-piperidinophenyl)-1-butylamine
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CN102267959B (zh) * 2011-07-06 2013-05-01 海南锦瑞制药股份有限公司 一种瑞格列奈晶体、其制备方法及含有该晶体的固体口服制剂
CN103012319B (zh) * 2011-09-20 2015-06-10 浙江九洲药业股份有限公司 瑞格列奈中间体的合成工艺改进
CN102584743A (zh) * 2011-12-28 2012-07-18 中国药科大学 对二甲氨基吡啶瑞格列奈共晶
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
NZ710574A (en) 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CA2918077A1 (fr) 2013-07-25 2015-01-29 Novartis Ag Bioconjugues de polypeptides d'apeline synthetiques
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
WO2016073615A1 (fr) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Sels et compositions utiles pour le traitement de maladie
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
WO2018034627A1 (fr) 2016-08-18 2018-02-22 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Composition pharmaceutique de comprimé antidiabétique
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347565A1 (de) * 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
EP0589874A1 (fr) 1994-04-06
FI935724A0 (fi) 1993-12-20
AU8078191A (en) 1993-01-25
NO303687B1 (no) 1998-08-17
EP0589874B1 (fr) 1999-09-08
NO934726D0 (no) 1993-12-20
SG43036A1 (en) 1997-10-17
JP2921982B2 (ja) 1999-07-19
CN1048722C (zh) 2000-01-26
WO1993000337A1 (fr) 1993-01-07
FI935724A (fi) 1993-12-20
JPH06508816A (ja) 1994-10-06
NO934726L (no) 1993-12-20
CN1068820A (zh) 1993-02-10
NO1999017I1 (no) 1999-07-20
AU660930B2 (en) 1995-07-13

Similar Documents

Publication Publication Date Title
FI106027B (fi) Menetelmä (S)(+)-2-etoksi-4-[N-[1-(2-piperidinofenyyli)-3-metyyli-1-butyyli] aminokarbonyylimetyyli]-betsoehapon tai sen suolan valmistamiseksi sekä (S)-1-(2-piperidinofenyyli)-3-metyyli-1-butyyliamiinin N-asetyyli-L-glutamiinisuola sen valmistus
NZ274849A (en) Benzoyl guanidine derivatives, preparation and pharmaceutical compositions thereof
CA2107223C (fr) Chlorhydrate de tiagabine monohydrate cristallin, sa preparation et son utilisation
EP3889147A1 (fr) 4-({(2s)-2-[4-{5-chloro-2-[4-(trifluorométhyl)-1h-1,2,3-triazol-1-yl]phényl}-5-méthoxy-2-oxopyridin-1(2h)-yl]butanoyl}-amino)-2-fluorobenzamide acétone et son utilisation
EP1861389A1 (fr) Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique
HUT61727A (en) Process for producing 1-(2-arylethyl)-pyrrolidines and pharmaceutical compositions comprising same
MXPA02001599A (es) Derivados de bencimidazol sustituidos con aminocarbonilo, procedimiento para su preparacion su utilizacion como medicamentos.
CA2111851C (fr) Acide (s)(+)-2-ethoxy-4-{n-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl}benzoique
JPH08301831A (ja) スチルベン誘導体及びそれを含有する制癌剤
US4073929A (en) 3-(2-Substitutedbenzimidazolyl) alanines
KR100496720B1 (ko) (s)(+)-2-에톡시-4[n-[1-(2-피페리디노페닐)-3-메틸-1-부틸]아미노카보닐메틸]-벤조산을함유하는당뇨병치료제
HRP940769A2 (en) (s)(+)-2-ethoxy-4-(n-(1-(2-piperidinophenyl)-3-methyl-1-butyl)-aminocarbonylmethyl)benzoic acid, medicines containing them, that compound and processes for the preparation thereof
AU646276B2 (en) Acid addition salts of optically active alaninanilide compounds and pharmaceutical compositions containing the same
CN116082259B (zh) 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂
IE912519A1 (en) Benzoic acid derivative
IE85730B1 (en) Benzoic acid derivative
SI9111136A (en) (S)-(+)-2-ethoxy-4-/N-/1-(2-piperidino-phenyl)-3-methyl-1-butyl/ aminocarbonylmethyl/-benzoic acid, pharmaceuticals containing this compaund and processes for their preparation
SK281246B6 (sk) Kyselina (s)(+)-2-etoxy-4-(n-(1-(2-piperidino-fenyl)-3-metyl-1- -butyl)-aminokarbonylmetyl)-benzoová, farmaceutické kompozície s jej obsahom, spôsob jej prípravy, medziprodukty na jej prípravu a jej použitie
CZ280430B6 (cs) Kyselina (S)(+)-2-ethoxy-4-/N-/1-(2-piperidinofenyl)-3-methyl-1-butyl/aminokarbonylmethyl/benzoová, farmaceutické prostředky s jejím obsahem, její použití a meziprodukty pro její výrobu
CN108329282B (zh) 一种苯基哌嗪类衍生物及其制备方法和应用
HU211240A9 (hu) Hipoglikémiás hatással rendelkező (S)-(+)-2-etoxi-4-[{N-1-(2-piperidino-fenil)-3-metil-butil]-karbamoil}-metil·]- benzoesav vagy hidrátja vagy gyógyszerészetileg elfogadható sója Az átmeneti oltalom az igénypontra vonatkozik.
US5371088A (en) 1-aryl-4-piperazinylcyclohexanecarbonitriles, the preparation and use thereof
EP0965591A1 (fr) (s)-3-methyl-1-(2-piperidino-phényl-1-butylamine, ses sels, synthèse et utilisation dans la thérapie de longue durée de la diabète mellitus
KR20070113272A (ko) 피로글루타메이트 염 및 덱스트로세티리진 및레보세티리진을 합성하기 위한 중간체의 광학 분리에서의이들의 용도
HU215921B (hu) Eljárás (S)-(+)-2-etoxi-4-[{N-/1-(2-piperidino-fenil)-3-metil-butil/-karbamoil}-metil]-benzoesav és ezt tartalmazó gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: NOVO NORDISK A/S

Free format text: NOVO NORDISK A/S

MA Patent expired